Healthcare provider profile · identity verified

Natalia Polyakova

Internal Medicine · YONKERS, NY · NPI 1578718920

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	494	153
Atorvastatin Calcium	Atorvastatin Calcium	409	149
Hydrochlorothiazide	Hydrochlorothiazide	234	76
Metformin Hcl	Metformin Hcl	206	67
Losartan Potassium	Losartan Potassium	169	57
Lisinopril	Lisinopril	166	60
Eliquis	Apixaban	156	36
Metoprolol Succinate	Metoprolol Succinate	154	54
Albuterol Sulfate Hfa	Albuterol Sulfate	148	39
Simvastatin	Simvastatin	131	41
Omeprazole	Omeprazole	130	42
Levothyroxine Sodium	Levothyroxine Sodium	119	38
Tamsulosin Hcl	Tamsulosin Hcl	100	28
Januvia	Sitagliptin Phosphate	98	24
Gabapentin	Gabapentin	97	35
Rosuvastatin Calcium	Rosuvastatin Calcium	95	42
Fluticasone Propionate	Fluticasone Propionate	83	34
Zolpidem Tartrate	Zolpidem Tartrate	78	17
Famotidine	Famotidine	75	27
Mirtazapine	Mirtazapine	75	24
Triamcinolone Acetonide	Triamcinolone Acetonide	75	27
Glimepiride	Glimepiride	72	22
Valsartan	Valsartan	71	28
Pantoprazole Sodium	Pantoprazole Sodium	70	26
Metoprolol Tartrate	Metoprolol Tartrate	69	24
Pravastatin Sodium	Pravastatin Sodium	69	21
Furosemide	Furosemide	68	21
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	60	16
Metformin Hcl Er	Metformin Hcl	54	20
Ozempic	Semaglutide	54	12
Montelukast Sodium	Montelukast Sodium	51	17
Nifedipine Er	Nifedipine	51	23
Tramadol Hcl	Tramadol Hcl	51	suppressed
Atenolol	Atenolol	44	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	44	14
Allopurinol	Allopurinol	43	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	43	17
Telmisartan	Telmisartan	42	12
Synthroid	Levothyroxine Sodium	39	15
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	39	17
Enalapril Maleate	Enalapril Maleate	38	suppressed
Ezetimibe	Ezetimibe	38	14
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	38	11
Ventolin Hfa	Albuterol Sulfate	38	suppressed
Alendronate Sodium	Alendronate Sodium	36	suppressed
Sertraline Hcl	Sertraline Hcl	36	15
Ibuprofen	Ibuprofen	35	14
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	34	suppressed
Irbesartan	Irbesartan	34	11
Meclizine Hcl	Meclizine Hcl	33	14
Naproxen	Naproxen	32	suppressed
Carvedilol	Carvedilol	31	15
Oxycodone Hcl	Oxycodone Hcl	31	suppressed
Hydrocortisone	Hydrocortisone	30	suppressed
Prednisone	Prednisone	30	23
Trazodone Hcl	Trazodone Hcl	29	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	28	suppressed
Glipizide Er	Glipizide	27	suppressed
Lovastatin	Lovastatin	27	suppressed
Felodipine Er	Felodipine	26	suppressed
Jardiance	Empagliflozin	26	11
Clopidogrel	Clopidogrel Bisulfate	25	suppressed
Finasteride	Finasteride	24	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	24	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	22	suppressed
Entresto	Sacubitril/Valsartan	21	suppressed
Meloxicam	Meloxicam	21	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	20	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	20	suppressed
Ramipril	Ramipril	20	suppressed
Trulicity	Dulaglutide	20	suppressed
Valacyclovir	Valacyclovir Hcl	20	suppressed
Breo Ellipta	Fluticasone/Vilanterol	19	suppressed
Levetiracetam	Levetiracetam	19	suppressed
Myrbetriq	Mirabegron	19	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	19	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	18	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	18	suppressed
Mounjaro	Tirzepatide	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Benazepril Hcl	Benazepril Hcl	17	suppressed
Duloxetine Hcl	Duloxetine Hcl	17	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	17	suppressed
Verapamil Er	Verapamil Hcl	17	suppressed
Alprazolam	Alprazolam	16	suppressed
Diclofenac Sodium	Diclofenac Sodium	16	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Propranolol Hcl Er	Propranolol Hcl	16	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	16	13
Clonazepam	Clonazepam	15	suppressed
Gemfibrozil	Gemfibrozil	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Nystatin-Triamcinolone	Nystatin/Triamcinolone Acet	15	suppressed
Azelastine Hcl	Azelastine Hcl	14	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Glipizide	Glipizide	14	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	13	suppressed
Azithromycin	Azithromycin	13	suppressed
Ciclopirox	Ciclopirox Olamine	13	suppressed
Digoxin	Digoxin	13	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	13	suppressed
Methimazole	Methimazole	13	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	13	suppressed
Potassium Chloride	Potassium Chloride	13	suppressed
Torsemide	Torsemide	13	suppressed
Tradjenta	Linagliptin	13	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	12	suppressed
Single Use Swab	Alcohol Antiseptic Pads	12	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed
Topiramate	Topiramate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error